Format

Send to:

Choose Destination
See comment in PubMed Commons below
Drug Discov Today. 2007 Jul;12(13-14):540-7. Epub 2007 Jun 27.

Preclinical and clinical safety of monoclonal antibodies.

Author information

  • 1AstraZeneca Inc., 24500 Clawiter Road, Hayward, CA 94545, USA. mohammad.tabrizi@astrazeneca.com

Abstract

Owing to their unique specificity, monoclonal antibodies have provided a novel approach to the treatment of human diseases. Several types of antibodies against a diverse array of pharmacological targets have been marketed and many more are currently in clinical trials. Factors related to antigen expression, target pharmacology, and antibody effector functions can contribute to the adverse event profiles observed with monoclonal antibodies. Effective translation of information gained from preclinical research and safety studies into clinical development is a crucial step for successful development of monoclonal antibodies.

PMID:
17631248
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science
    Loading ...
    Write to the Help Desk